Terumo Corporation
Based in Japan, Terumo Corporation is a global medical technology company with a strong presence in the cardiovascular market. Their commitment to innovation has made them a leading player in cardiac tissue engineering, notably with their product HeartSheet. This advanced therapy is derived from autologous skeletal myoblast sheets and is designed to treat heart failure resulting from chronic ischemic disease. HeartSheet was approved under Japan’s accelerated regulatory framework for regenerative medicine, showcasing Terumo’s capability for swift development and application of advanced cardiac technologies. Beyond this innovative product, Terumo’s extensive cardiovascular division offers a broad range of solutions, including devices that replicate heart and lung functions during surgery, and their comprehensive approach reinforces their leadership in delivering advanced cardiac care solutions globally.
Latest Market Research Report on Cardiac Tissue Engineering Download PDF Brochure Now
Artivion, Inc.
Artivion, Inc., formerly known as CryoLife Inc., is a U.S.-based company recognized in the cardiac tissue engineering market for its expertise in products for cardiac and vascular surgical procedures. The company specializes in developing innovative solutions, particularly for patients with aortic disease. A cornerstone of their portfolio is SynerGraft, a flagship product engineered to support natural tissue regeneration while mitigating the risk of immune rejection. SynerGraft acts as a scaffold that enhances the effectiveness and biocompatibility of implantable human tissues. Artivion’s products demonstrate a deep understanding of the complexities involved in cardiovascular surgery. With an extensive global presence across North America, Europe, and Asia Pacific, Artivion reinforces its leadership by providing high-quality, advanced medical devices and implantable human tissues to address critical needs in cardiac care worldwide.
Baxter International Inc.
Baxter International Inc. is a global leader in medical technology and regenerative therapies, playing a prominent role in the cardiac tissue engineering market, primarily through its Advanced Surgery segment. The company focuses on developing products that contribute to the regeneration and repair of tissues used in complex surgical procedures. Their notable offerings for cardiothoracic surgery include Peri-Guard and Supple Peri-Guard. These products are crafted from bovine pericardium, which is a key biomaterial used for cardiac applications. These products are known for their high safety profile and efficacy, with an exceptionally low reported adverse event rate. Baxter’s dedication to pushing the boundaries of medical technology, coupled with its extensive global distribution network, solidifies its position as a major provider of high-quality, effective biomaterial products essential for advancing cardiothoracic surgery and cardiac tissue engineering.
Edwards Lifesciences
Edwards Lifesciences is a U.S.-based global company recognized as the leading innovator in structural heart disease technologies. While they are primarily known for their advanced medical devices, their work is fundamentally intertwined with the application of biomaterials and tissue-based solutions in cardiac care, particularly for valve replacement. They pioneered the development of transcatheter heart valves and continue to advance transcatheter mitral and tricuspid technologies. The company is driven by a patient-focused passion to help individuals fighting cardiovascular disease. Their innovative technologies for surgical valve and transcatheter therapies often utilize advanced tissue processing to ensure product longevity and performance. Edwards Lifesciences’ role in constantly driving new solutions for heart valve failure places them as a core, enabling force in the broader field of cardiac regenerative and structural engineering.
Vascudyne
Vascudyne, an innovative U.S. company, specializes in Engineered Tissue Solutions, striving to become a world leader in tissue engineering and regenerative therapies. Their mission is to develop world-class regenerative solutions for an expanding range of medical needs, including cardiovascular, vascular, and neurological applications. In cardiac tissue engineering, Vascudyne focuses on critical products such as Coronary Artery Bypass Grafts, Heart Valve Replacements, and Pediatric Cardiovascular Conduits and Patches. Their core technology involves a unique biologically-engineered matrix, conduit, and valve technologies, co-invented by their expert team. This platform enables them to engineer and grow human tissues in various shapes and sizes. By providing completely biological tissues, Vascudyne aims to revolutionize the healthcare industry and provide uncompromising quality and longevity in cardiovascular repair.
Avery Therapeutics
Avery Therapeutics is a U.S.-based, preclinical-stage biopharmaceutical company focused on developing first-in-class tissue-engineered therapeutics. The company has made a significant mark in the cardiac tissue engineering space with its lead program, MyCardia. MyCardia is an immunologically compatible, tissue-engineered heart graft specifically designed to treat coronary issues in humans and improve heart function following myocardial infarction (heart attack). The therapeutic is intended for local administration, which aims to prevent the pathological changes that lead to heart failure. Avery Therapeutics leverages its expertise in cell and gene therapy to create these advanced engineered tissues, showcasing an innovative approach to redirecting the immune system and addressing the devastating effects of cardiac disease and fibrosis, positioning them as a key startup to watch in the field.
Cellular Logistics
Cellular Logistics, based in Madison, Wisconsin, is a biotechnology startup that is dedicated to cardiac tissue regeneration through the development of an acellular biomaterial platform. Their lead therapeutic biomaterial, CFX (Cardiac Fibroblast matriX), is produced using induced pluripotent stem cell (iPSC) technology. CFX is designed for local administration to the heart muscle after a heart attack to prevent the negative remodeling that often leads to heart failure. The acellular platform is intended to act as an Extracellular Matrix (ECM) scaffold, which facilitates better cell therapy delivery and retention. Cellular Logistics’ approach leverages the body’s natural healing pathways and ECM components to enable the regeneration of damaged cardiac tissue, demonstrating a sophisticated, modern solution for treating ischemic heart disease.
Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology, Inc. (HART), based in Massachusetts, is a company focused on developing and commercializing bioengineered organs and tissues for transplantation and regenerative medicine applications. HART has a specific focus in the cardiac tissue engineering market on creating a bioengineered cardiac tissue patch. This patch has the potential to repair damaged heart tissue, directly addressing a critical unmet need for heart failure patients. The company’s strategy centers on a strong commitment to research and development in regenerative medicine, which allows them to remain at the forefront of innovation in this complex field. By focusing on the development of a beating heart patch, HART is working to provide innovative solutions that can restore function to the failing myocardium.
CorMatrix Cardiovascular, Inc.
CorMatrix Cardiovascular, Inc. is a medical device company based in Georgia, specializing in the development and commercialization of biomaterials for cardiovascular applications. Their core competency lies in the utilization of their proprietary extracellular matrix (ECM) technology. In the cardiac tissue engineering market, CorMatrix has developed a bioresorbable cardiac patch. This patch is engineered to promote natural tissue repair and regeneration after implantation. The company’s strength is its strong intellectual property portfolio and established reputation in the field of cardiovascular biomaterials. By creating a scaffold that the patient’s body can naturally remodel, CorMatrix aims to offer a less invasive and more biologically integrated solution for repairing damaged heart tissue, thereby mitigating the need for permanent synthetic materials.
Acell Inc.
Acell Inc., a regenerative medicine company headquartered in Maryland, is focused on creating products that facilitate tissue regeneration and repair across various medical fields. In the context of cardiac tissue engineering, Acell has a key focus on the development of a bioactive graft. This graft is specifically designed to stimulate endogenous cell migration and differentiation, which are crucial natural processes for cardiac tissue regeneration. The company’s approach centers on providing a supportive scaffold that encourages the body’s own healing mechanisms to repair damaged myocardial tissue. Acell’s diverse portfolio of regenerative medicine products and its strong network of research collaborators solidify its position as an important player in providing biological solutions for tissue repair in the cardiovascular space.
Tissx
Tissx is a supplier that sources, manufactures, and supplies tissue products and services for various specialty surgeries, including cardiac and vascular applications. Tissx is committed to making high-quality, affordable tissue products available globally. Their product development is directly relevant to cardiac tissue engineering as they develop and manufacture products such as fixed pericardial tissue patches and valve repair products. The company also collaborates with other corporations by providing OEM (Original Equipment Manufacturer) services and developing tissue bioprosthetics. Tissx plays a vital role in the cardiac tissue engineering ecosystem by providing essential, high-quality human and animal-derived tissue components and OEM support needed for the creation of advanced surgical grafts and bioprosthetic heart valves.
Cuorips
Cuorips is a Japanese company that is highly focused on developing next-generation cell-based therapies for cardiac repair. Their specialty lies in the creation of iPS cell-derived cardiomyocyte sheets. Induced pluripotent stem (iPS) cells are adult cells that have been genetically reprogrammed to an embryonic-like state, which can then differentiate into any cell type, including the beating cells of the heart (cardiomyocytes). By manufacturing these cells into sheet form, Cuorips aims to provide a functional patch that can be transplanted onto damaged areas of the heart to restore myocardial function, offering a revolutionary solution for treating heart failure that leverages the power of regenerative medicine and advanced cell sheet technology.
Repairon
Repairon, based in Göttingen, Germany, is a company dedicated to heart repair using innovative cellular technology. Their core activity in cardiac tissue engineering involves leveraging induced pluripotent stem cells (iPSC) to create tissue for heart repair. The focus on iPSCs allows them to generate patient-specific or highly compatible cardiac cells, which can then be organized into functional tissue constructs. Repairon’s work contributes to the development of regenerative therapies that aim to replace scar tissue in the heart with new, functional heart muscle. This cell-based strategy represents a cutting-edge approach to addressing heart failure by improving cardiac function through the transplantation of bioengineered, living heart tissue.
Latest Market Research Report on Cardiac Tissue Engineering Download PDF Brochure Now